Re-biopsy in a patient with IgA nephropathy showing success of treatment with cyclosporin A and angiotensin-II receptor blocker

被引:3
|
作者
Machiguchi T. [1 ]
Tei M. [1 ]
Ono T. [2 ]
Kambara H. [1 ]
机构
[1] Department of Internal Medicine, Osaka Red Cross Hospital, Osaka 543-8555, 5-53 Fudegasaki-cho, Tennoji-ku
[2] Department of Cardiovascular Medicine, Kyoto University Graduate, School of Medicine, Kyoto
关键词
Angiotensin-II receptor blocker; Cyclosporin A; IgA nephropathy; Nephrotic syndrome;
D O I
10.1007/s101570200029
中图分类号
学科分类号
摘要
We report a patient with IgA nephropathy (IgAN) showing reduction of proteinuria and histological improvement of renal injury with cyclosporin A (CsA) and angiotensin-II receptor blocker (ARB) therapy. The amount of urinary protein was reduced from 4.4 to 1.8g/24h after 2 months of CsA (150mg/day) therapy, and further, to 0.4g/24h after 1 month of the combination therapy with ARB (candesartan, 4mg/day). A renal re-biopsy, after treatment with CsA for 3 months and ARB for 1 month, demonstrated a reduction of IgA deposits, disappearance of crescents, re-separation of foot process fusion and decrease of interstitial cellular infiltration. After CsA therapy for 20 months and ARB for 18 months, the patient currently remains stable without deterioration of serum creatinine (1.7mg/dl) and urinary protein excretion (0.5g/day). These findings seem to indicate that combination therapy with CsA and ARB is effective for achieving histological improvement and protecting against deteriorated renal function, in addition to reducing proteinuria, in IgAN. © Japanese Society of Nephrology 2002.
引用
收藏
页码:166 / 169
页数:3
相关论文
共 23 条
  • [1] Combined treatment of prednisolone and angiotensin II receptor blocker in IgA nephropathy.
    Ihm, CG
    Lee, SH
    Lee, SH
    Kim, YH
    Lee, T
    Kim, MJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 752A - 752A
  • [2] Sparsentan Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist Treatment of focal segmental glomerulosclerosis Treatment of IgA nephropathy
    Trachtman, H.
    Hogan, J. J.
    Tesar, V
    Komers, R.
    DRUGS OF THE FUTURE, 2020, 45 (02) : 79 - 98
  • [4] ALDOSTERONE BREAKTHROUGH DURING COMBINED ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND ANGIOTENSIN II RECEPTOR BLOCKER IN PATIENTS WITH IGA NEPHROPATHY
    Horita, Yoshio
    Tadokoro, Masato
    Taura, Kouichi
    Taguchi, Takashi
    Miyazaki, Masanobu
    Kohno, Shigeru
    NEPHROLOGY, 2005, 10 : A37 - A37
  • [5] Effect of valsartan, an angiotensin II AT1 receptor blocker, on the glomerular fibrosis of IgA nephropathy in ddY mice
    Suzuki, Y
    Thang, NT
    Horikoshi, S
    Shirato, I
    Nakamura, S
    Kimura, M
    Tomino, Y
    NEPHRON, 2000, 86 (03): : 374 - 375
  • [6] Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy
    Yang, Y
    Ohta, K
    Shimizu, M
    Nakai, A
    Kasahara, Y
    Yachie, A
    Koizumi, S
    CLINICAL NEPHROLOGY, 2005, 64 (01) : 35 - 40
  • [7] Augmentation of antiproteinuric effect by combined therapy with angiotensin II receptor blocker plus calcium channel blocker in a hypertensive patient with IgA glomerulonephritis
    Kuriyama, S
    Tomonari, H
    Abe, A
    Kunieda, T
    Hosoya, T
    JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (05) : 371 - 373
  • [8] Augmentation of antiproteinuric effect by combined therapy with angiotensin II receptor blocker plus calcium channel blocker in a hypertensive patient with IgA glomerulonephritis
    S Kuriyama
    H Tomonari
    A Abe
    T Kunieda
    T Hosoya
    Journal of Human Hypertension, 2002, 16 : 371 - 373
  • [9] Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy A systematic review
    Mavrakanas, Thomas A.
    Gariani, Karim
    Martin, Pierre-Yves
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2014, 25 (02) : 173 - 176
  • [10] Beneficial effect of Angiotensin-II type 1 receptor blocker antihypertensive treatment on arterial stiffness. The role of smoking
    Kyvelou, Stella-Maria
    Vyssoulis, Gregory
    Karpanou, Eva
    Adamopoulos, Dionyssis
    Vlachopoulos, Charalambos
    Antonakoudis, George
    Pietri, Panagiota
    Cokkinos, Dennis
    Stefanadis, Christodoulos
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 413A - 414A